浩欧博: 江苏浩欧博生物医药股份有限公司第三届监事会第二十次会议决议公告

Meeting Details - The third meeting of the supervisory board of Jiangsu Haobio Pharmaceutical Co., Ltd. was held on September 2, 2025, with all three supervisors present, and the meeting was chaired by Ms. Jiao Haiyun [1][2] - The meeting was convened in accordance with the Company Law of the People's Republic of China and the company's articles of association [1] Resolution Summary - The supervisory board concluded that the completion of the fundraising project "New In Vitro Diagnostic Reagent R&D Center Project" aligns with actual circumstances [1] - The decision-making process for this matter complies with relevant laws and regulations, including the "Regulations on the Supervision of Fundraising by Listed Companies" and the "Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board" [1] - The supervisory board approved the completion of certain fundraising projects [1][2] Voting Results - The voting results showed 3 votes in favor, 0 votes against, and 0 abstentions, indicating unanimous approval from all supervisors [2]